Icon (NASDAQ:ICLR) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of $1.41 per share for the quarter.

Shares of Icon (NASDAQ ICLR) opened at $109.55 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. The firm has a market cap of $5,920.00, a PE ratio of 21.27, a price-to-earnings-growth ratio of 1.51 and a beta of 0.48. Icon has a 1 year low of $76.46 and a 1 year high of $124.48.

A hedge fund recently raised its stake in Icon stock. Vanguard Group Inc. lifted its holdings in shares of Icon Plc (NASDAQ:ICLR) by 19.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,545 shares of the medical research company’s stock after buying an additional 2,400 shares during the quarter. Vanguard Group Inc.’s holdings in Icon were worth $1,422,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 89.66% of the company’s stock.

ICLR has been the subject of several research reports. Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $132.00 price objective for the company in a research report on Tuesday, January 9th. Mizuho set a $109.00 price objective on shares of Icon and gave the company a “hold” rating in a research report on Wednesday, January 24th. BidaskClub upgraded shares of Icon from a “strong sell” rating to a “sell” rating in a research report on Friday. SunTrust Banks restated a “buy” rating and issued a $138.00 price objective on shares of Icon in a research report on Sunday, October 29th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $120.00 price objective (up previously from $105.00) on shares of Icon in a research report on Monday, October 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $124.55.

COPYRIGHT VIOLATION WARNING: This article was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://theolympiareport.com/2018/02/13/icon-iclr-to-release-quarterly-earnings-on-thursday.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.